Menu
Close
Sign up for NPL updates
Close
Sign up for NPL updates

Receive regular emails from NPL to get a glimpse of our activities and see how our experts are informing and influencing scientific debate

Prof Philip Evans

Prof Philip Evans

Joint appointment

Philip completed a DPhil in physics in Oxford in 1988 before joining the Institute of Cancer Research and Royal Marsden Hospital as post-doctoral research fellow. He worked at ICR/RMH for many years, being made a professor in 2010. In 2012 he joined the Centre for Vision Speech and Signal Processing in the Department of Electrical and Electronic Engineering in the University of Surrey as Professor of Medical Radiation Imaging. He 2018 he started a joint appointment with NPL and CVSSP. His work has involved the first trial of Intensity Modulated Radiotherapy for breast cancer, the first demonstration of a megavoltage CT patient image on a radiotherapy treatment unit and the development of the widely used Spekcalc package to model x-ray spectra.

Philip has served on the editorial boards of several journals, has been advisor to IAEA on image guided radiotherapy and has been joint chair of workstream 4 of the NCRI Clinical and Translational Radiotherapy Research Working Group. Currently he is a member of the NIHR Doctoral Research Fellowship Panel and The Institute of Physics Fellowship Panel. He is a Fellow of the Institute of Physics, The Institute of Mathematics and Its Applications and The Institute of Physics and Engineering in Medicine. He has published 300 papers in international peer reviewed journals and has a h-index of 40 (Scopus).

Philip holds a joint post with The National Physical Laboratory and The University of Surrey plus an honorary position with The Royal Surrey County Hospital.

Areas of Interests

Philip’s areas of interest include applications of medical imaging to radiotherapy and cancer problems. He is working on the development, understanding and robustness of big data approaches to medical research, known as radiomics, the application of image techniques to problems in lung, breast, gynaecological and prostate cancer.

Proton radiotherapy is a new cancer treatment to the UK and he is developing models to understand the fundamental limits of imaging in proton radiotherapy and proton image reconstruction methods.

The MR linac offers a step change in image guided radiotherapy and he is working on methods to standardise the calibration of these new systems.

Email Philip